Aspira Women's Health FY2022 revenue $8.2M (+20% YoY); Q4 cash burn $7.1M

Aspira Women's Health Inc.

Full-year revenue $8.2M, up 20% from $6.8M; OvaSuite volume 21,423 units (+23% YoY).
Gross margin improved to 53% (FY) vs 45% in 2021; Q4 gross margin 57% vs 55%.
Cash and short-term investments $13.6M at year-end; 2023 cash utilization guided $16-19M.
OvaWatch launched late 2022; March 2023 coverage secured from major national payer.
EndoCheck (endometriosis blood test) development on track for 2023 launch target.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aspira Women's Health Inc. reported the three months ended December 31, 2022 results: revenue $2.2 million.

Period: the three months ended December 31, 2022
Revenue: $2.2 million
Result: reported results

Exact text from the filing

Total revenue for the three months ended December 31, 2022 was $2.2 million, an increase of 16% compared to $1.9 million for the same period in 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aspira Women's Health Inc. reported the year ended December 31, 2022 results: revenue $8.2 million.

Period: the year ended December 31, 2022
Revenue: $8.2 million
Result: reported results

Exact text from the filing

Total revenue was $8.2 million for the year ended December 31, 2022, an increase of 20% compared to $6.8 million for the same period in 2021.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0000926617-23-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.